India’s Drug controller general of India(DCGI) gives permission to Bharat Biotech for Phase -3 clinical trials after completion of Phase -1 and Phase 2 trials of COVAXIN. The phase-3 clinical trials will be done in 25 centre in 26,000 participants across India.
In a recent case, a 38-year-old woman faced a life-altering health crisis while six months…
The intricate relationship between hormonal contraception and breast cancer risk has once again come into…
Diabetes is a chronic condition that affects how your body processes blood sugar (glucose). When…
A recent study published in the journal Clinical Nutrition highlights significant concerns regarding ultra-processed foods…
Air pollution is often portrayed as an environmental concern, but its impact on human health…
Delhi, the bustling capital of India, has long been grappling with an escalating environmental crisis—air…